Alpha 1-antitrypsin: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

edit
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Available structures
1atu, 1d5s, 1ezx, 1hp7, 1iz2, 1kct, 1oo8, 1oph, 1psi, 1qlp, 1qmb, 2d26, 7api, 8api, 9api
Identifiers
Symbols SERPINA1; PI; A1A; A1AT; AAT; MGC23330; MGC9222; PI1; PRO2275
External IDs OMIM107400 MGI891971 HomoloGene20103 GeneCards: SERPINA1 Gene
RNA expression pattern
PBB GE SERPINA1 211429 s at tn.png
PBB GE SERPINA1 202833 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 5265 20700
Ensembl ENSG00000197249 ENSMUSG00000071178
UniProt P01009 Q3KQQ4
RefSeq (mRNA) NM_000295 NM_009243
RefSeq (protein) NP_000286 NP_033269
Location (UCSC) Chr 14:
93.91 - 93.92 Mb
Chr 12:
104.13 - 104.14 Mb
PubMed search [3] [4]

Alpha 1-Antitrypsin or α1-antitrypsin (A1AT) is a glycoprotein and generally known as serum trypsin inhibitor. Alpha 1- antitrypsin is also referred to as alpha-1 proteinase inhibitor (A1PI) because it is a serine protease inhibitor (serpin), inhibiting a wide variety of proteases.[1] It protects tissues from enzymes of inflammatory cells, especially elastase, and has a reference range in blood of 1.5 - 3.5 gram/liter (in US the reference range is generally expressed as mg/dL or micromoles), but the concentration can rise manyfold upon acute inflammation.[2] In its absence, elastase is free to break down elastin, which contributes to the elasticity of the lungs, resulting in respiratory complications such as emphysema, or COPD (chronic obstructive pulmonary disease) in adults and cirrhosis in adults or children.

Contents

Function

A1AT is a 52-kDa serpin (serine protease inhibitor), and, in medicine, it is considered the most prominent serpin; the terms α1-antitrypsin and protease inhibitor (Pi) are often used interchangeably.

Most serpins inactivate enzymes by binding to them covalently, requiring very high levels to perform their function. In the acute phase reaction, a further elevation is required to "limit" the damage caused by activated neutrophil granulocytes and their enzyme elastase, which breaks down the connective tissue fiber elastin.

Like all serine protease inhibitors, A1AT has a characteristic secondary structure of beta sheets and alpha helices. Mutations in these areas can lead to non-functional proteins that can polymerise and accumulate in the liver (infantile hepatic cirrhosis).

Role in disease

Disorders of this protein include alpha 1-antitrypsin deficiency, a hereditary disorder in which a deficiency of alpha 1-antitrypsin leads to a chronic uninhibited tissue breakdown. This causes the degradation especially of lung tissue, and eventually leads to characteristic manifestations of pulmonary emphysema.[3] Evidence has shown that cigarette smoke can lead to oxidation of methionine 358 of α1-antitrypsin, a residue essential for binding elastase; this is thought to be one of the primary mechanisms by which cigarette smoking (or second-hand smoke) can lead to emphysema. Because A1AT is created in the liver, certain mutations in the DNA code for the enzyme can cause misfolding and impaired secretion of the enzyme, which can lead to liver cirrhosis.

A remarkable form of Pi, termed PiPittsburgh, functions as an antithrombin (a related serpin), due to a mutation (Met358Arg). One patient with this abnormality has been described; he died of a lethal bleeding diathesis.

Liver biopsy will show abundant PAS-positive globules within periportal hepatocytes.

Nomenclature

The protein was originally named "antitrypsin" because of its ability to covalently bind and irreversibly inactivate the enzyme trypsin in vitro. Trypsin, a type of peptidase, is a digestive enzyme active in the duodenum and elsewhere.

The term alpha-1 refers to the protein's behavior on protein electrophoresis. On electrophoresis, the protein component of the blood is separated by electric current. There are several clusters, the first being albumin, the second being the alpha, the third beta and the fourth gamma (immunoglobulins). The non-albumin proteins are referred to as globulins.

The alpha region can be further divided into two sub-regions, termed "1" and "2". Alpha 1-antitrypsin is the main enzyme of the alpha-globulin 1 region.

Another name used is alpha-1 proteinase inhibitor1-PI).

Genetics

The gene is located on the long arm of the fourteenth chromosome (14q32.1).

Over 100 different variants of α1-antitrypsin have been described in various populations. North-Western Europeans are most at risk for carrying one of the most common mutant forms of A1AT, the Z mutation.

Biochemical Properties

A1AT is a single-chain glycoprotein consisting of 394 amino acids in the mature form. The three N-linked glycosylations sites are mainly equipped with so-called diantennary N-glycans. However, one particular site shows a considerable amount of heterogeneity since tri- and even tetraantennary N-glycans can be attached to the Asparagine 107 (ExPASy amino acid nomenclature). These glycans carry different amounts of negatively-charged sialic acids, this causes the heterogeneity observed on normal A1AT when analysed by isoelectric focussing. In addition, the fucosylated triantennary N-glycans were shown to have the fucose as part of a so-called Sialyl Lewis x epitope, which could confer this protein particular protein-cell recognition properties. The single cysteine residue of A1AT in position 256 (ExPASy nomenclature) is found to be covalently linked to a free single cysteine by a disulfide bridge.[4]

Analysis

As protein electrophoresis is imprecise, A1AT is analysed by isoelectric focusing (IEF) in the pH range 4.5-5.5, where the protein migrates in a gel according to its isoelectric point or charge in a pH gradient.

Normal A1AT is termed M, as it is migrates toward the center of such an IEF gel. Other variants are less functional, and are termed A-L and N-Z, dependent on whether they run proximal or distal to the M band. The presence of deviant bands on IEF can signify the presence of alpha 1-antitrypsin deficiency. Since the number of identified mutations has exceeded the number of letters in the alphabet, subscripts have been added to most recent discoveries in this area, as in the Pittsburgh mutation described above.

As every person has two copies of the A1AT gene, a heterozygote with two different copies of the gene may have two different bands showing on electrofocusing, although heterozygote with one null mutant that abolishes expression of the gene will only show one band.

In blood test results, the IEF results are notated as in PiMM, where Pi stands for protease inhibitor and "MM" is the banding pattern of that patient.

Other detection methods include use of enzyme-linked-immuno-sorbent-assays in vitro and radial immunodiffusion.

Alpha 1-antitrypsin levels in the blood depend on the genotype. Some mutant forms fail to fold properly and are, thus, targeted for destruction in the proteasome, whereas others have a tendency to polymerise, being retained in the endoplasmic reticulum. The serum levels of some of the common genotypes are:

  • PiMM: 100% (normal)
  • PiMS: 80% of normal serum level of A1AT
  • PiSS: 60% of normal serum level of A1AT
  • PiMZ: 60% of normal serum level of A1AT
  • PiSZ: 40% of normal serum level of A1AT
  • PiZZ: 10-15% (severe alpha 1-antitrypsin deficiency)

Other rarer forms have been described; in all there are over 80 variants.

Therapeutic use

Alpha 1-antitrypsin
Systematic (IUPAC) name
Alpha-1-proteinase inhibitor
Identifiers
CAS number 9041-92-3
ATC code B02AB02
PubChem  ?
DrugBank BTD00002
Chemical data
Formula C 2001H3130N514O601S10  
Mol. mass 44324.5 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes intravenous

Recombinant alpha 1-antitrypsin is not yet commercially available, but is under investigation as a therapy for alpha 1-antitrypsin deficiency.

Therapeutic concentrates are prepared from the blood plasma of blood donors. The US FDA has approved the use of three alpha 1-antitrypsin products derived from a human plasma: Prolastin, Zemaira, and Aralast. These products for intravenous augmention A1AT therapy can cost up to $100,000 per year per patient[5]. They are administered intravenously at a dose of 60 mg/kg once a week.

A recent study analyzed and compared the three FDA-approved products in terms of their primary structure and glycosylation. All three products showed minor differences compared to the normal human plasma A1AT, and are introduced during the specific purifications procedures. However, these detected differences are not believed to have any negative implications to the patients.[6]

Aerosolized-augmented A1AT therapy is under study. This involves inhaling purified human A1AT into the lungs and trapping the A1AT into the lower respiratory tract. This method proves more successful than intravenous-augmented A1AT therapy because intravenous use of A1AT results in only 10%-15% of the A1AT reaching the lower respiratory tract, whereas 25%-45% of A1AT can reach the lower respiratory tract through inhalation. However, inhaled A1AT may not reach the elastin fibers in the lung where elastase injury actually occurs. Further study is clearly warranted.

History

The possibility of allelic variants of A1AT leading to disease was first investigated by Axelsson and Laurell in 1965.[7]

See also

References

  1. ^ Gettins PG (2002). "Serpin structure, mechanism, and function". Chem Rev 102 (12): 4751–804. doi:10.1021/cr010170. PMID 12475206.  
  2. ^ Kushner, Mackiewicz A (1993). The acute phase response: an overview.. CRC Press. pp. 3–19.  
  3. ^ DeMeo DL, Silverman EK (2004). "Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk". Thorax 59 (3): 259–64. doi:10.1136/thx.2003.006502. PMID DOI [http://dx.doi.org/10.1136/thx.2003.006502 10.1136/thx.2003.006502 14985567 DOI 10.1136/thx.2003.006502].  
  4. ^ Kolarich D, Weber A, Turecek PL, Schwarz HP, Altmann F (2006). "Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms". Proteomics 6 (11): 3369–80. doi:10.1002/pmic.200500751. PMID DOI [http://dx.doi.org/10.1002/pmic.200500751 16622833 DOI [1]].  
  5. ^ Alkins SA, O'Malley P (2000). "Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis". Chest 117 (3): 875–80. doi:10.1378/chest.117.3.875. PMID 10713018.  
  6. ^ Kolarich D, Turecek PL, Weber A, Mitterer A, Graninger M, Matthiessen P, Nicolaes GA, Altmann F, Schwarz HP (2006). "Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy". Transfusion 46 (11): 1959–77. doi:10.1111/j.1537-2995.2006.01004.x. PMID DOI [http://dx.doi.org/10.1111/j.1537-2995.2006.01004.x 17076852 DOI [2]].  
  7. ^ Axelsson U, Laurell CB (1965). "Hereditary variants of serum alpha-1-antitrypsin". Am J Hum Genet 17 (6): 466–72. PMID 4158556.  

Further reading

  • Wu Y, Foreman RC (1991). "The molecular genetics of alpha 1 antitrypsin deficiency". Bioessays 13 (4): 163–9. doi:10.1002/bies.950130404. PMID 1859394.  
  • Kalsheker N (1989). "Alpha 1-antitrypsin: structure, function and molecular biology of the gene". Biosci. Rep. 9 (2): 129–38. doi:10.1007/BF01115992. PMID 2669992.  
  • Crystal RG (1990). "The alpha 1-antitrypsin gene and its deficiency states". Trends Genet. 5 (12): 411–7. doi:10.1016/0168-9525(89)90200-X. PMID 2696185.  
  • Carrell RW, Jeppsson JO, Laurell CB, et al. (1982). "Structure and variation of human alpha 1-antitrypsin". Nature 298 (5872): 329–34. doi:10.1038/298329a0. PMID 7045697.  
  • Elliott PR, Abrahams JP, Lomas DA (1998). "Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation". J. Mol. Biol. 275 (3): 419–25. doi:10.1006/jmbi.1997.1458. PMID 9466920.  
  • Miyamoto Y, Akaike T, Maeda H (2000). "S-nitrosylated human alpha(1)-protease inhibitor". Biochim. Biophys. Acta 1477 (1-2): 90–7. PMID 10708851.  
  • Coakley RJ, Taggart C, O'Neill S, McElvaney NG (2001). "Alpha1-antitrypsin deficiency: biological answers to clinical questions". Am. J. Med. Sci. 321 (1): 33–41. PMID 11202478.  
  • Lomas DA, Lourbakos A, Cumming SA, Belorgey D (2002). "Hypersensitive mousetraps, alpha1-antitrypsin deficiency and dementia". Biochem. Soc. Trans. 30 (2): 89–92. doi:10.1042/BST0300089. PMID 12023831.  
  • Kalsheker N, Morley S, Morgan K (2002). "Gene regulation of the serine proteinase inhibitors alpha1-antitrypsin and alpha1-antichymotrypsin". Biochem. Soc. Trans. 30 (2): 93–8. doi:10.1042/BST0300093. PMID 12023832.  
  • Perlmutter DH (2003). "Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury". J. Clin. Invest. 110 (11): 1579–83. PMID 12464659.  
  • Lomas DA, Mahadeva R (2003). "Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy". J. Clin. Invest. 110 (11): 1585–90. PMID 12464660.  
  • Lisowska-Myjak B (2005). "AAT as a diagnostic tool". Clin. Chim. Acta 352 (1-2): 1–13. doi:10.1016/j.cccn.2004.03.012. PMID 15653097.  
  • Lomas DA (2005). "Molecular mousetraps, alpha1-antitrypsin deficiency and the serpinopathies". Clinical medicine (London, England) 5 (3): 249–57. PMID 16011217.  
  • Rudnick DA, Perlmutter DH (2005). "Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease". Hepatology 42 (3): 514–21. doi:10.1002/hep.20815. PMID 16044402.  
  • Mahr AD, Neogi T, Merkel PA (2006). "Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants". Clin. Exp. Rheumatol. 24 (2 Suppl 41): S82–91. PMID 16859601.  
  • González-Sagrado M, López-Hernández S, Martín-Gil FJ, et al. (2000). "Alpha1-antitrypsin deficiencies masked by a clinical capillary electrophoresis system (CZE 2000)". Clinical Biochemistry, 33(1):79–80

Links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message